Deerfield Management Company, L.P. (Series C) Editas Medicine, Inc. Put Options Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding EDIT
# of Institutions
248Shares Held
57MCall Options Held
410KPut Options Held
394K-
Black Rock Inc. New York, NY7.78MShares$15.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.68MShares$13.3 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.9MShares$9.75 Million0.62% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.35MShares$6.67 Million0.01% of portfolio
-
State Street Corp Boston, MA2.46MShares$4.9 Million0.0% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $137M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...